Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,346.92 84.36 0.52%
S&P 500 1,854.45 11.47 0.62%
NASDAQ 4,048.25 14.09 0.35%
Ticker Volume Price Price Delta
STOXX 50 3,131.11 39.59 1.28%
FTSE 100 6,575.78 34.17 0.52%
DAX 9,292.39 118.68 1.29%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

RBCC Joint Venture’s Technology Could Lead to Cancer-Fighting Breakthrough



  RBCC Joint Venture’s Technology Could Lead to Cancer-Fighting Breakthrough

Business Wire

NOKOMIS, Fla. -- November 12, 2012

Advanced cell-culturing technology developed by Nano3D BioSciences (n3D), the
joint venture partner of Rainbow Coral Corp.’s (OTCBB: RBCC) biotech
subsidiary Rainbow Biosciences, will soon be put to use reducing cancer risks
caused by obesity.

Following the publication of a study co-authored by n3D’s Dr. Glauco Souza
demonstrating the effectiveness of the n3D Bio-Assembler in culturing
three-dimensional tissues from stem cells, the device will immediately be put
to use in cutting-edge cancer research.

Dr. Mikhail Kolonin, an associate professor at the University of Texas Health
Science Center at Houston, is the author of a new study detailing how
cancerous tumors actually “feed” on fat cells. His research, published in the
journal Cancer Research and it is entitled “Stromal progenitor cells from
endogenous adipose tissue contribute to pericytes and adipocytes that populate
the tumor microenvironment,” proves that actual stem cells from fat were
migrating through the bloodstream in mice and lodging in tumors, helping them
to grow and build blood vessels.

In essence, the tumors were fattening up at the cellular level.

For the next phase of this research, n3D’s Bio-Assembler will be crucial. The
direction of this work is to use human cells paired with magnetically
levitated three-dimensional cell culturing. This research will shed new light
on the relationship between cancer and obesity in a human tissue
microenvironment, potentially leading to new drugs capable of “starving”
tumors and dramatically reducing cancer risks from obesity.

“This will be exactly the sort of high-profile research that the n3D
Bio-Assembler was designed to facilitate,” said RBCC CEO Patrick Brown. “When
the results of this new study are published in respected medical journals,
researchers around the world are going to want to harness the power of the
Bio-Assembler to advance their own work.”

The Bio-Assembler’s fusion of magnetic levitation and nanoparticle assembly
technologies allow it to produce accurate, 3D representations of in vivo
tissues faster and easier than any competing tools. The groundbreaking device
is key to RBCC’s plans to participate in the impressive upside in store for
n3D.

RBCC’s relationship with n3D is only one of the partnerships putting the
company on the cutting edge of biotech innovation. Last week, RBCC finalized a
new joint venture with Amarantus BioSciences (OTCBB: AMBS), the makers of a
game-changing diagnostic blood test for Parkinson’s disease.

Rainbow BioSciences is dedicated to developing new medical and research
technology innovations to compete alongside companies such as Amgen Inc.
(NASDAQ: AMGN), Cell Therapeutics, Inc. (NASDAQ: CTIC) and Abbott Laboratories
(NYSE: ABT).

For more information on Rainbow BioSciences, please visit
www.rainbowbiosciences.com/investors.

Follow us on Twitter at www.twitter.com/RBCCinfo.

About Rainbow BioSciences

Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC). The
company continually seeks out new partnerships with biotechnology developers
to deliver profitable new medical technologies and innovations. For more
information on our growth-oriented business initiatives, please visit our
website at www.rainbowbiosciences.com. For investment information and
performance data on the company, please
visit www.RainbowBioSciences.com/investors.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the company assumes no responsibility to update the information included
herein for events occurring after the date hereof.

Contact:

Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
info@rainbowcoral.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement